StockData
Mesoblast Ltd logo

Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.91−0.54 (-4.34%)

Close on Nov 17, 2026Market cap $1.54BP/E –Yield –

Mesoblast price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Mesoblast's price to sales ratio was 14.7× on Nov 11, 2026, against 121.0× a year earlier. Over the last 5 years it ranged from 14.7× to 336.7×, with a median of 69.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202614.7×−112.0
2025Dec 31, 2025126.7×−204.3
2024Dec 31, 2024331.0×+308.2
2023Dec 29, 202322.8×−27.0
2022Dec 30, 202249.8×−11.6
2021Dec 31, 202161.4×+4.5
2020Dec 31, 202056.9×+23.7
2019Dec 31, 201933.1×+19.1
2018Dec 31, 201814.1×−179.2
2017Dec 29, 2017193.2×+184.1
2016Dec 30, 20169.2×–

More Mesoblast figures

See a number that looks wrong?